News Related to ACTRIMS

Related coverage linked through entity extraction aliases.

Daratumumab Shows Promise in NMOSD as FDA Accepts Iberdomide NDA for Multiple Myeloma

May 02, 2026

Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.

Fenebrutinib Shows 12% Reduction in Disability Progression vs Ocrelizumab in PPMS Trial

Feb 25, 2026

Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.